VEGFR-2(KDR)抗体与妇科恶性肿瘤

The application of anti-VEGFR2 in gynecologic malignant tumors

血管内皮细胞生长因子(vascular endothelial growth factor,VEGF)是一种具有较高特异性的血管生成因子,VEGF通过与血管内皮细胞生长因子受体家族(vascular endothelial growth factor receptor family,VEGFRs)相互作用,促进血管内皮细胞和淋巴内皮细胞的增殖和分化、调节血管通透性,从而在生理性和病理性血管形成过程中发挥调节作用。近年来,以VEGF及其受体为靶点的抗肿瘤治疗受到越来越多的关注,妇产科常见三大恶性肿瘤:卵巢癌、子宫内膜癌及宫颈癌的发展与VEGF、VEGFR2的表达也存在相关性,本文重点介绍以VEGFR2为靶点的抗肿瘤治疗在卵巢癌、子宫内膜癌及宫颈癌中的研究进展。

Vascular endothelial growth factor（VEGF） is a kind of angiogenesis factor which functions through binding to vascular endothelial growth factor receptor family（VEGFRs） with high specificity. It promotes the proliferation and differentiation of vascular endothelial cells and lymphatic endothelial cells and regulates vascular permeability, thus playing a regulatory role in the physiological and pathological angiogenesis process. Recently, more and more attention has been paid to the anti-tumor therapy targeting at VEGF and its receptors. The expressions of VEGF and VEGFR-2 have relationships with the progression of ovarian cancer,endometrial cancer and cervical cancer-the three commonest gynecologic malignant tumors. This paper aims to introduce the research progress of anti-tumor therapy targeting at VEGFR-2 in these three cancers.